Qiagen N.V. (QIAN.MX)
| Previous close | 757.36 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 784.36 - 784.36 |
| 52-week range | 721.91 - 898.11 |
| Volume | |
| Avg. volume | 536 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 16.53 |
| EPS (TTM) | 47.46 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireQIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
GlobeNewswireQIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
Simply Wall St.Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for Qiagen N.V. ( NYSE:QGEN ) shareholders, because the company has just released its latest...
